831 related articles for article (PubMed ID: 17355741)
21. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy.
Shin DH; McCracken MS; Bendel RE; Pearlman R; Juzych MS; Hughes BA; Schulz LL; Kim C; Baek NH
Ophthalmology; 1999 Feb; 106(2):386-90. PubMed ID: 9951495
[TBL] [Abstract][Full Text] [Related]
22. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
[TBL] [Abstract][Full Text] [Related]
23. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides.
Martínez A; Sánchez M
Curr Med Res Opin; 2007 Mar; 23(3):595-9. PubMed ID: 17355740
[TBL] [Abstract][Full Text] [Related]
24. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
van der Valk R; Webers CA; Schouten JS; Zeegers MP; Hendrikse F; Prins MH
Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
[TBL] [Abstract][Full Text] [Related]
25. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
26. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
Arcieri ES; Pierre Filho PT; Wakamatsu TH; Costa VP
Eye (Lond); 2008 Feb; 22(2):179-83. PubMed ID: 16936646
[TBL] [Abstract][Full Text] [Related]
27. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
28. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
Reardon G; Schwartz GF; Mozaffari E
Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
30. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension.
Hepsen IF; Ozkaya E
Eye (Lond); 2007 Apr; 21(4):453-8. PubMed ID: 16543930
[TBL] [Abstract][Full Text] [Related]
31. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; Hoop J; Morgan L; Wudunn D; Catoira Y;
Br J Ophthalmol; 2006 Nov; 90(11):1370-3. PubMed ID: 16825272
[TBL] [Abstract][Full Text] [Related]
32. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials.
Simmons ST; Dirks MS; Noecker RJ
Adv Ther; 2004; 21(4):247-62. PubMed ID: 15605619
[TBL] [Abstract][Full Text] [Related]
33. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
34. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
[TBL] [Abstract][Full Text] [Related]
35. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.
Katz LJ; Cohen JS; Batoosingh AL; Felix C; Shu V; Schiffman RM
Am J Ophthalmol; 2010 Apr; 149(4):661-671.e1. PubMed ID: 20346780
[TBL] [Abstract][Full Text] [Related]
36. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
37. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
39. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
40. Effect of ketorolac add-on treatment on intra-ocular pressure in glaucoma patients receiving prostaglandin analogues.
Turan-Vural E; Torun-Acar B; Acar S
Ophthalmologica; 2012; 227(4):205-9. PubMed ID: 22116588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
